KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Tax Provisions (2016 - 2025)

Pfizer (PFE) has disclosed Tax Provisions for 17 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 99.52% to -$2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$266.0 million, a 850.0% decrease, with the full-year FY2025 number at -$266.0 million, down 850.0% from a year prior.
  • Tax Provisions was -$2.0 million for Q4 2025 at Pfizer, up from -$216.0 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.6 billion in Q3 2022 to a low of -$964.0 million in Q4 2023.
  • A 5-year average of $182.9 million and a median of $69.5 million in 2025 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: surged 208.54% in 2022, then plummeted 370.79% in 2023.
  • Pfizer's Tax Provisions stood at -$328.0 million in 2021, then soared by 208.54% to $356.0 million in 2022, then tumbled by 323.31% to -$795.0 million in 2023, then skyrocketed by 47.04% to -$421.0 million in 2024, then surged by 99.52% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Tax Provisions are -$2.0 million (Q4 2025), -$216.0 million (Q3 2025), and $141.0 million (Q2 2025).